Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:
“Pregnancy and Thrombosis: Balancing Evolutionary Protection Against Clinical Risk
Why does pregnancy multiply a patient’s risk of Venous Thromboembolism (VTE) by 4 to 5 times?
From a physiological standpoint, it is a masterclass in evolutionary survival.
To protect the mother from lethal hemorrhage during placental delivery, the female body enters a state of profound hypercoagulability.
However, this protective mechanism pushes the hemostatic curve to a razor-thin edge, fulfilling all three pillars of Virchow’s Triad:
- Hypercoagulability: A systemic shift favoring clotting, driven by an increase in procoagulant factors (Fibrinogen, FVIII, VWF) paired with a physiological decline in natural anticoagulants like Protein S.
- Stasis: Mechanical compression of the inferior vena cava and pelvic veins by the gravid uterus severely impedes lower extremity venous return.
- Endothelial Alterations: Micro-vascular stress induced by rapid hemodynamic fluctuations during gestation and delivery.
The clinical stakes are high, and the window of maximum vulnerability is counterintuitive: the risk peaks not during the third trimester, but during the first 6 weeks of the postpartum period.
Evaluating underlying thrombophilia (such as Factor V Leiden, Prothrombin G20210A mutations, or Antiphospholipid Syndrome) without being misled by normal, pregnancy-induced biochemical baselines remains one of the most delicate challenges in laboratory medicine today.
Bridging Laboratory Insights and Bedside Decisions
Because this balance between life-saving hemostasis and life-threatening thrombosis remains a critical puzzle, it will be a focal point of global clinical discussion this summer.
The ISTH 2026 Congress (International Society on Thrombosis and Haemostasis), taking place in Paris from July 11–15, 2026, is dedicating multiple specialized sessions to
Hemostasis and Women’s Health.
Top global experts will present the latest clinical trials, long-term safety data on low-molecular-weight heparin (LMWH) prophylaxis, and emerging molecular biomarkers for early risk stratification.
If you are attending ISTH2026, these sessions are unmissable for anyone looking to refine their clinical protocols in obstetric hematology.
Let’s advance the science of maternal health together.
See you in Paris!”

Find more posts featuring Bruno Pougault on Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics